Experimental CAR-T therapy targets tough childhood blood cancers
Disease control
Not yet recruiting
This early-phase trial is testing a new treatment called PA3-17 injection for children and teens aged 3 to 18 with T-cell leukemia or lymphoma that has not responded to standard therapy or has come back. The treatment uses the patient's own immune cells, modified to recognize and…
Phase: PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC